Rabies is a public health problem in Asia and vaccine affordability is an issue. There is no reduction in the number of persons seeking post-exposure prophylaxis. The high cost of cell culture vaccines for intramuscular use is a limiting factor. Intradermal rabies vaccination offers cost-effective alternative to intramuscular. WHO recommended one week intradermal schedule will ensure good patient compliance.